Novo Nordisk has agreed to buy Akero Therapeutics and its drug candidate for metabolic dysfunction-associated steatohepatitis (MASH) for $4.7 billion upfront, shortly after claiming FDA approval to ...
After several quarters on a steady sales roll as the world’s first treatment for metabolic dysfunction-associated steatohepatitis (MASH), the pressure is on for Madrigal Pharmaceuticals’ Rezdiffra ...
If you happen to have some leftover mash or pick up a pack from the reduced section of the supermarket, these crispy, cheesy potato cakes are the perfect thing to make! Each potato cake provides 138 ...
Metabolic dysfunction-associated steatohepatitis (MASH), formerly nonalcoholic steatohepatitis (NASH), involves liver fat buildup that triggers inflammation and damage. The name change aims to be more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results